249 related articles for article (PubMed ID: 12374779)
1. Protection of innate immunity by C5aR antagonist in septic mice.
Huber-Lang MS; Riedeman NC; Sarma JV; Younkin EM; McGuire SR; Laudes IJ; Lu KT; Guo RF; Neff TA; Padgaonkar VA; Lambris JD; Spruce L; Mastellos D; Zetoune FS; Ward PA
FASEB J; 2002 Oct; 16(12):1567-74. PubMed ID: 12374779
[TBL] [Abstract][Full Text] [Related]
2. Role of C5a-C5aR interaction in sepsis.
Guo RF; Riedemann NC; Ward PA
Shock; 2004 Jan; 21(1):1-7. PubMed ID: 14676676
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil C5a receptor and the outcome in a rat model of sepsis.
Guo RF; Riedemann NC; Bernacki KD; Sarma VJ; Laudes IJ; Reuben JS; Younkin EM; Neff TA; Paulauskis JD; Zetoune FS; Ward PA
FASEB J; 2003 Oct; 17(13):1889-91. PubMed ID: 12897064
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a functional role of the second C5a receptor C5L2.
Gao H; Neff TA; Guo RF; Speyer CL; Sarma JV; Tomlins S; Man Y; Riedemann NC; Hoesel LM; Younkin E; Zetoune FS; Ward PA
FASEB J; 2005 Jun; 19(8):1003-5. PubMed ID: 15784721
[TBL] [Abstract][Full Text] [Related]
5. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis.
Riedemann NC; Guo RF; Hollmann TJ; Gao H; Neff TA; Reuben JS; Speyer CL; Sarma JV; Wetsel RA; Zetoune FS; Ward PA
FASEB J; 2004 Feb; 18(2):370-2. PubMed ID: 14688199
[TBL] [Abstract][Full Text] [Related]
6. Complement-induced impairment of innate immunity during sepsis.
Huber-Lang MS; Younkin EM; Sarma JV; McGuire SR; Lu KT; Guo RF; Padgaonkar VA; Curnutte JT; Erickson R; Ward PA
J Immunol; 2002 Sep; 169(6):3223-31. PubMed ID: 12218141
[TBL] [Abstract][Full Text] [Related]
7. Anti-complement strategies in experimental sepsis.
Ward PA; Riedemann NC; Guo RF; Huber-Lang M; Sarma JV; Zetoune FS
Scand J Infect Dis; 2003; 35(9):601-3. PubMed ID: 14620141
[TBL] [Abstract][Full Text] [Related]
8. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.
Heller T; Hennecke M; Baumann U; Gessner JE; zu Vilsendorf AM; Baensch M; Boulay F; Kola A; Klos A; Bautsch W; Köhl J
J Immunol; 1999 Jul; 163(2):985-94. PubMed ID: 10395696
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.
Riedemann NC; Neff TA; Guo RF; Bernacki KD; Laudes IJ; Sarma JV; Lambris JD; Ward PA
J Immunol; 2003 Jan; 170(1):503-7. PubMed ID: 12496437
[TBL] [Abstract][Full Text] [Related]
10. C5a receptor and thymocyte apoptosis in sepsis.
Riedemann NC; Guo RF; Laudes IJ; Keller K; Sarma VJ; Padgaonkar V; Zetoune FS; Ward PA
FASEB J; 2002 Jun; 16(8):887-8. PubMed ID: 12039868
[TBL] [Abstract][Full Text] [Related]
11. Anaphylatoxin C5a-induced toll-like receptor 4 signaling in bovine neutrophils.
Stevens MG; Van Poucke M; Peelman LJ; Rainard P; De Spiegeleer B; Rogiers C; Van de Walle GR; Duchateau L; Burvenich C
J Dairy Sci; 2011 Jan; 94(1):152-64. PubMed ID: 21183027
[TBL] [Abstract][Full Text] [Related]
12. Increased C5a receptor expression in sepsis.
Riedemann NC; Guo RF; Neff TA; Laudes IJ; Keller KA; Sarma VJ; Markiewski MM; Mastellos D; Strey CW; Pierson CL; Lambris JD; Zetoune FS; Ward PA
J Clin Invest; 2002 Jul; 110(1):101-8. PubMed ID: 12093893
[TBL] [Abstract][Full Text] [Related]
13. A key role of C5a/C5aR activation for the development of sepsis.
Riedemann NC; Guo RF; Ward PA
J Leukoc Biol; 2003 Dec; 74(6):966-70. PubMed ID: 12960283
[TBL] [Abstract][Full Text] [Related]
14. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice.
Shagdarsuren E; Bidzhekov K; Mause SF; Simsekyilmaz S; Polakowski T; Hawlisch H; Gessner JE; Zernecke A; Weber C
Circulation; 2010 Sep; 122(10):1026-36. PubMed ID: 20733098
[TBL] [Abstract][Full Text] [Related]
15. The harmful role of c5a on innate immunity in sepsis.
Ward PA
J Innate Immun; 2010; 2(5):439-45. PubMed ID: 20588003
[TBL] [Abstract][Full Text] [Related]
16. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of C5a blockade in sepsis.
Czermak BJ; Sarma V; Pierson CL; Warner RL; Huber-Lang M; Bless NM; Schmal H; Friedl HP; Ward PA
Nat Med; 1999 Jul; 5(7):788-92. PubMed ID: 10395324
[TBL] [Abstract][Full Text] [Related]
18. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease.
Shushakova N; Skokowa J; Schulman J; Baumann U; Zwirner J; Schmidt RE; Gessner JE
J Clin Invest; 2002 Dec; 110(12):1823-30. PubMed ID: 12488432
[TBL] [Abstract][Full Text] [Related]
19. C5a, a therapeutic target in sepsis.
Guo RF; Ward PA
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):57-65. PubMed ID: 18221134
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of anti-C5a peptide antibodies in experimental sepsis.
Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Guo RF; Padgaonkar VA; Younkin EM; Laudes IJ; Riedemann NC; Younger JG; Ward PA
FASEB J; 2001 Mar; 15(3):568-70. PubMed ID: 11259369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
